Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.79−0.31 (-0.19%)
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis Net Sales in Rest of World: $478M in Q3 2026, up 21.3% from a year earlier.
Latest, Q3 2026
478
Period ended Sep 30, 2026
Change on a year earlier
+21.3%
394 in Q3 2025
History
19 quarters
Since Q1 2022
Sources
19
Documents cited below
Where the Q3 2026 figure comes from
“|| Kesimpta | Neuroscience | Relapsing forms of multiple sclerosis (MS) | 1 006 | 21 | 478 | 21 | 23 | 1 484 | 21 | 22”
Source: Novartis Form 6-K (0001114448-26-000014) ↗
Reported in Form 6-K & Form 20-F (Top 20 Brands US / Rest of World).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up net Sales in Rest of World
Cite this data
StockData. (2026). Novartis Net Sales in Rest of World ($M), quarterly Q1 2022–Q3 2026 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-kesimpta-row-sales
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.